menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Navigating the Evolving Landscape: Advanced Decision-Making in ATTR-CM

Master ATTR-CM! Our program gives pharmacists actionable strategies and real-world best practices for improved early detection and patient outcomes.

Live Meeting
1.50 available credits
Information
April 29, 2024
05:30 PM - 07:30 PM PST
Wynn and Encore Las Vegas
3131 Las Vegas Blvd., Room: Lafite 3, Las Vegas, Nevada, United States
ReachMD Healthcare Image
Details
Presenters
Related
Comments
  • Overview

    Expand your expertise in managing transthyretin amyloid cardiomyopathy (ATTR-CM) with our program designed for specialty pharmacists. Our expert-led sessions will provide an in-depth review of the latest on this disease landscape, including genetic variations, evolving patient profiles, and the most up-to-date data. You'll explore the growing field of ATTR-CM therapies and gain insights into how specialty pharmacies can ensure patient access to these treatments. Learn how to interpret clinical trial data on emerging therapies, effectively apply your knowledge in real-world situations, and ultimately elevate the standard of care for your ATTR-CM patients.

  • Program Schedule

    Coming soon!

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Jennifer L. Day, PharmD
    Clinical Transplant Pharmacist
    Baptist Health Heart Failure and Transplant Institute
    Little Rock, AR

    Dr. Day has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Consulting Fees: Janssen Pharmaceuticals

    Faculty:
    Courtney M. Campbell, MD, PhD
    Cardiovascular Disease, Cardio-Oncology
    Baylor Scott & White
    Dallas, TX

    Dr. Campbell has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Alnylam Pharmaceuticals, Inc., Pfizer  
    Research: Akari Therapeutics, Alnylam Pharmaceuticals, Pfizer 

    Dejan Landup, PharmD, HF-Cert
    Cardiovascular Clinical Pharmacist
    Heart Failure and Chronic Disease Management Clinic
    Advocate Medical Group - Evergreen Center
    Chicago, IL

    No relevant relationships have been reported at this time.

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose. 
    • Howard Green has nothing to disclose. 
    • Andrea Mathis has nothing to disclose. 
    • Tim Person has nothing to disclose. 
    • Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals. 
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiology and genetic variation of transthyretin amyloid cardiomyopathy (ATTR-CM)
    • Discuss the clinical manifestations and diagnosis of ATTR-CM
    • Compare the treatment options available for patients with ATTR-CM
  • Target Audience

    This activity is designed to meet the educational needs of pharmacists, primary care physicians, and advanced practice providers. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.  

    Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-023-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)


    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from BridgeBio.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Mdtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Details
Presenters
Related
Comments
Recommended
  • Overview

    Expand your expertise in managing transthyretin amyloid cardiomyopathy (ATTR-CM) with our program designed for specialty pharmacists. Our expert-led sessions will provide an in-depth review of the latest on this disease landscape, including genetic variations, evolving patient profiles, and the most up-to-date data. You'll explore the growing field of ATTR-CM therapies and gain insights into how specialty pharmacies can ensure patient access to these treatments. Learn how to interpret clinical trial data on emerging therapies, effectively apply your knowledge in real-world situations, and ultimately elevate the standard of care for your ATTR-CM patients.

  • Program Schedule

    Coming soon!

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Jennifer L. Day, PharmD
    Clinical Transplant Pharmacist
    Baptist Health Heart Failure and Transplant Institute
    Little Rock, AR

    Dr. Day has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Consulting Fees: Janssen Pharmaceuticals

    Faculty:
    Courtney M. Campbell, MD, PhD
    Cardiovascular Disease, Cardio-Oncology
    Baylor Scott & White
    Dallas, TX

    Dr. Campbell has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Alnylam Pharmaceuticals, Inc., Pfizer  
    Research: Akari Therapeutics, Alnylam Pharmaceuticals, Pfizer 

    Dejan Landup, PharmD, HF-Cert
    Cardiovascular Clinical Pharmacist
    Heart Failure and Chronic Disease Management Clinic
    Advocate Medical Group - Evergreen Center
    Chicago, IL

    No relevant relationships have been reported at this time.

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose. 
    • Howard Green has nothing to disclose. 
    • Andrea Mathis has nothing to disclose. 
    • Tim Person has nothing to disclose. 
    • Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals. 
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiology and genetic variation of transthyretin amyloid cardiomyopathy (ATTR-CM)
    • Discuss the clinical manifestations and diagnosis of ATTR-CM
    • Compare the treatment options available for patients with ATTR-CM
  • Target Audience

    This activity is designed to meet the educational needs of pharmacists, primary care physicians, and advanced practice providers. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.  

    Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-023-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)


    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from BridgeBio.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Mdtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Facebook Comments

Schedule17 May 2024